MBI's Intra-Articular Injection with 90% Satisfaction Receives TGA Approval in Australia

ArtiBest one-dose intra-articular injection successfully obtains TGA certification, poised to bring significant business opportunities for Australian customers.

As Australia becomes the second most aged country globally, the annual compound growth rate for joint health demand is projected to be 13% over the next five years.

ArtiBest one-dose intra-articular injection, leveraging the exclusive ECHA cross-linking technology, offers quality comparable to international brands while maintaining a price advantage of 10-15%. Clinical data shows a user satisfaction rate of up to 90%, establishing it as Taiwan’s leading hyaluronic acid brand.

ArtiBest is expected to help clients enhance brand loyalty and stimulate sales, making it an excellent opportunity to expand market share and increase profit margins.

Choose ArtiBest one-dose intra-articular injection for a win-win partnership!
Contact us now for more information!